Clinical Trial Update: Unboosted Atazanavir as Initial ART Therapy in China

View source ↗

Summary

A completed trial evaluating unboosted atazanavir as initial antiretroviral therapy in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• atazanavir (Reyataz) (atazanavir)

Snippet

Sponsor: National Center for AIDS/STD Control and Prevention, China CDC | Conditions: Antiretroviral Therapy | Status: COMPLETED